Kairos Pharma, LTD. KAPA
are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in
immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer,
lung cancer, breast cancer, and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies
to treat cancer.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D | $2.1M | $414.0K | $82.0K | — |
| SG&A | $3.4M | $1.9M | $1.6M | — |
| Total operating expenses | $5.6M | $2.3M | $1.7M | — |
| Operating income | -$5.6M | -$2.3M | -$1.7M | — |
| Interest expense | — | $35.0K | $42.0K | — |
| Net income | -$5.4M | -$2.6M | -$1.8M | — |
| EPS, basic | -0.30 | -0.23 | -0.17 | — |
| EPS, diluted | -0.30 | -0.23 | -0.17 | — |
| Shares, diluted (wtd. avg.) | 18.4M | 11.4M | 10.4M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $4.5M | $1.3M | $93.0K | $437.0K |
| Total current assets | $5.4M | $4.2M | $101.0K | — |
| Other intangibles | $62.0K | $222.0K | $382.0K | — |
| Total assets | $6.5M | $5.8M | $965.0K | — |
| Accounts payable | $199.0K | $992.0K | $2.4M | — |
| Total current liabilities | $199.0K | $992.0K | $2.4M | — |
| Total liabilities | — | $992.0K | $3.0M | — |
| Retained earnings | -$14.3M | -$8.8M | -$6.2M | — |
| Total equity | $6.3M | $4.8M | -$2.1M | -$1.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$3.4M | -$4.0M | $81.0K | — |
| Financing cash flow | $6.7M | $5.1M | -$425.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-014159.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Net income | — | -$1.8M | -$2.6M | -$5.4M |
Recent filings and events
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event Item 8.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed Item 1.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |